GlassScriptPhysician profile
Frederic A Humphrey
NPI 1366438848
$5,755.32
in general payments reported to CMS, 2019-2025
33 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $252 · 2021: $795 · 2022: $792 · 2023: $1,015 · 2024: $1,229 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,504.22 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,110.79 | 2021-2025 | |
| Amgen INC. | $819.12 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $399.34 | 2022-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $236.48 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $180.70 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $144.35 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Avanir Pharmaceuticals, INC. | $125.53 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $120.89 | 2020-2022 | |
| Pfizer INC. | $114.22 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.49 | 2019-2024 | Xifaxan |
| Allergan, INC. | $102.25 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.51 | 2023-2025 | Caplyta |
| Dexcom, INC. | $83.22 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $79.16 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $71.80 | 2019-2023 | Yupelri |
| Vanda Pharmaceuticals INC. | $61.15 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $49.08 | 2023-2025 | |
| Celgene Corporation | $46.16 | 2021-2023 | Zeposia |
| Abbott Laboratories | $44.07 | 2023-2024 | Proclaim, Freestyle Libre 3 |
| Verona Pharma, INC. | $38.72 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $38.08 | 2021 | |
| Novo Nordisk INC | $27.56 | 2019-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $27.01 | 2022 | |
| Lilly USA, LLC | $21.18 | 2021 | |
| Insulet Corporation | $18.26 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $17.58 | 2025 | Voquezna |
| Lundbeck LLC | $15.71 | 2022 | |
| Amarin Pharma, INC. | $14.47 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.96 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.60 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.